D
EEP VEIN THROMBOSIS AND pulmonary embolism are usually treated with a minimum of 5 days of heparin therapy overlapped with warfarin, which is continued for at least 3 months. 1 Unfractionated heparin, given by continuous intravenous infusion with ongoing dose adjustment in response to measurements of the activated partial thromboplastin time (APTT) has been the standard approach to initial treatment. Low-molecularweight heparin administered subcutaneously in fixed weight-adjusted doses is gradually replacing unfractionated heparin.
1 Subcutaneous administration without laboratory monitoring makes low-molecular-weight heparin suitable for outpatient treatment, which, despite the higher cost of lowmolecular-weight heparin compared with unfractionated heparin, greatly reduces health care costs. 1, 2 Although current practice is to administer unfractionated heparin by intravenous infusion and to adjust the dose based on APTT results, this may not be necessary or optimal. Trials that compared administration of unfractionated heparin by subcutaneous injections with intravenous infusion for initial treatment of venous thromboembolism have found that the subcutaneous route was at least as effective and safe. 3, 4 Whether given subcutaneously or intravenously, the dose of unfractionated heparin was adjusted in response to APTT values in previous studies. However, APTT measurements are of uncertain clinical relevance in patients who are being treated with heparin because they differ depending on the reagents and coagulometers used for the test, 5 they are increased by concomitant warfarin therapy, 6 and they have an uncertain relationship to efficacy and safety. Although some analyses have shown an association between low APTT values during heparin therapy and risk of recurrent venous thromboembolism, the studies included in these analyses often started with a dose of heparin that was lower than is currently recommended. [7] [8] [9] In analyses that only included studies in which patients received currently recommended initial doses of heparin, there was no association between low APTT values and recurrent venous thromboembolism. [10] [11] [12] Similarly, there is no clear association between high APTT values and risk of bleeding, independent of the dose of heparin that is administered. 13, 14 Furthermore, earlier studies that used heparin to treat venous thromboembolism did not chose an initial heparin dose that was proportional to patient weight, whereas weight-based dosing of initial heparin therapy is now recommended. 12, 15 If unfractionated heparin could be administered by subcutaneous injection without coagulation monitoring, it would make it easier to use and suitable for outpatient treatment of venous thromboembolism and would provide a less expensive alternative to low-molecular-weight heparin. We therefore performed a randomized trial comparing unfractionated heparin with low-molecular-weight heparin for initial treatment of venous thromboembolism. Both drugs were given subcutaneously, twice daily, in fixed weight-adjusted doses. Our hypothesis was that, used in this way, unfractionated heparin would be as effective and safe as low-molecularweight heparin.
METHODS

Study Patients
Patients aged 18 years or older with newly diagnosed deep vein thrombosis of the legs or pulmonary embolism were potentially eligible. Patients could have symptomatic deep vein thrombosis or asymptomatic deep vein thrombosis that was identified by screening of high-risk postoperative patients. Symptomatic proximal deep vein thrombosis was diagnosed by compression ultrasonography or by venography. 16 Symptomatic deep vein thrombosis that was confined to the calf veins, as well as all asymptomatic deep vein thromboses, required diagnosis by contrast venography. 16 Pulmonary embolism was symptomatic and objectively diagnosed by a highprobability ventilation-perfusion lung scan, by nondiagnostic findings on lung scan accompanied by diagnostic findings for deep vein thrombosis, or by presence of a segmental or more proximal pulmonary artery filling defect on computed tomographic angiography. 17 Patients who met the inclusion criteria were ineligible if they had a contraindication to subcutaneous therapy, such as shock or major surgery in the past 48 hours, had active bleeding, had a life expectancy of less than 3 months, had already received acute treatment for venous thromboembolism for more than 48 hours, were receiving longterm anticoagulant therapy, had a contraindication to heparin or to radiographic contrast, had a creatinine level of greater than 200 µmol/L (2.3 mg/ dL), were pregnant, were enrolled in a competing study, or were unable to have follow-up assessments because of geographic inaccessibility. There was no exclusion criterion for patient weight. Patients provided written informed consent, and the study was approved by the institutional review boards of all participating clinical centers.
Randomization and Treatment
Randomization was computergenerated with block sizes of 2 or 4, was stratified by clinical center, and was performed by having clinical centers telephone an automated centralized system. Patients were assigned to initial treatment with open-label unfractionated heparin (experimental group) or low-molecular-weight heparin (control group), each administered subcutaneously, twice daily, in doses that were determined by patient weight, and without subsequent use of coagulation tests to modify those doses (measurement of APTT or heparin levels by the clinical centers was prohibited) (FIGURE). Unfractionated heparin was given as a first dose of 333 U/kg, followed by subsequent doses of 250 U/kg (25 000 U/mL; multidose vials). 1, 18 This regimen was based on 3 factors: a requirement for a 10% higher dose when heparin is given subcutaneously, twice daily, compared with when heparin is given intravenously by continuous infusion 12, 19 ; acceptance that intravenously heparin should initially be given as a weight-based bolus of 80 U/kg, followed by an infusion of 18 U/kg per hour, when treating venous thromboembolism 12, 15 ; and results of a preliminary study that shows that therapeutic levels of anticoagulation would rapidly be achieved with the current subcutaneous regimen. 18 Lowmolecular-weight heparin was given at 100 IU/kg for all doses (10 000 IU/ mL; multidose vials). Subject to local availability, dalteparin or enoxaparin were the low-molecular-weight hepa-FIXED-DOSE UNFRACTIONATED HEPARIN FOR VENOUS THROMBOEMBOLISM rin preparations that were used. Unfractionated heparin or low-molecularweight heparin was given for at least 5 days and until the international normalized ratio was 2.0 or higher for 2 consecutive days. Warfarin was usually started the same day as heparin and was continued for a minimum of 3 months with doses adjusted to achieve an international normalized ratio of between 2.0 and 3.0.
Follow-up and Outcome Measures
Patients were assessed 3 days, 1 month, and 3 months after initiation of study drug treatment and were told to report immediately if they developed symptoms suggestive of venous thromboembolism or bleeding. Symptoms suggestive of recurrent venous thromboembolism were evaluated using standardized diagnostic testing as described previously. 20 To diagnose recurrent venous thromboembolism, the same criteria that were used to diagnose an initial episode of venous thromboembolism had to be satisfied in segments of the deep veins or pulmonary arteries that were previously unaffected with thrombosis. No routine testing was performed to detect asymptomatic extension or recurrence of thrombosis; therefore, all episodes of recurrent venous thromboembolism were associated with new symptoms. Sudden unexplained deaths were counted as pulmonary embolism. Bleeding was defined as major if it was clinically overt and associated with a decrease in hemoglobin level of at least 2.0 g/dL, involved a need for transfusion of 2 or more units of red blood cells, or involved a critical site (eg, retroperitoneal, intracranial). Platelet counts were not routinely monitored, but it was recorded if heparin therapy was stopped early because of thrombocytopenia. All outcome events and deaths were classified by a central adjudication committee whose members were unaware of treatment assignment.
Statistical Analyses
The trial was designed to determine if initial treatment with fixed-dose unfractionated heparin was as effective as (ie, not inferior to) treatment with lowmolecular-weight heparin. A frequency of recurrent venous thromboembolism of 6% in the 3 months after starting treatment was expected with low-molecular-weight heparin. [21] [22] [23] By consensus, arrived at by polling thromboembolism experts who planned to participate, it was decided that the study needed to have a 95% probability of detecting a higher frequency of recurrent thrombosis in the unfractionated heparin group (1-sided ␣=.05) if the unfractionated heparin regimen was truly associated with a 5% absolute increase in venous thromboembolism. In addition, the study was required to have a 90% power of concluding that unfractionated heparin was not less effective than low-molecular-weight heparin if the 2 treatments were truly equally effective. A study of 824 patients satisfies these requirements. 24 When, in conjunction with a slow rate of enrollment, a blinded interim analysis Competing Study *Patients could have more than 1 reason for exclusion. †Among the 11 patients who were not eligible for the analysis of efficacy, no follow-up was performed for 7 patients in the unfractionated heparin group (none known to have had recurrent venous thromboembolism or bleeding), follow-up was completed and was negative for venous thromboembolism and bleeding in the otherrevealed a lower-than-expected frequency of recurrent venous thromboembolism in all randomized patients combined, a decision was made by the steering committee to stop the study after 700 patients were enrolled.
The primary analysis for efficacy was the absolute difference in the proportion of eligible patients who had recurrent venous thromboembolism at 3 months. The primary analysis for safety was the absolute difference in the proportion of patients who received at least 1 dose of study drug who had an episode of major bleeding within 10 days of randomization. A small number of patients who underwent automated telephone randomization were not included in the analysis, mostly because they did not meet eligibility criteria (Figure) . The decision to exclude these patients from the safety and efficacy analyses was made by the steering committee without knowledge of patients' treatment allocations or their subsequent clinical course, and all such patients are described in this report. The Fisher exact test was used to compare proportions. Data were analyzed using SAS software, version 9.1 (SAS Institute Inc, Cary, NC) and StatXact software, version 7.0 (Cytel Corp, Boston, Mass).
Laboratory Assay
When feasible, a single blood sample was obtained from each patient 6 hours (between 3.0 and 9.9 hours was acceptable) after injection of unfractionated heparin on the third day (the second through sixth days were acceptable) of treatment for measurement of APTT using Thrombosil (Instrumentation Laboratory, Lexington, Mass) and an STA Compact coagulometer (Diagnostica Stago, Asnières sur Seine, France). All APTT measurements were performed in a centralized laboratory in Hamilton, Ontario, by technologists who were blinded to clinical information. Assays were performed after the study was completed, and the results were categorized as low if APTT was shorter than 60 seconds and high if APTT was longer than 85 seconds; these values corre- *Of the randomized patients, 2 who were allocated to the unfractionated heparin group and 1 who was allocated to the low-molecular-weight heparin group did not have baseline data recorded that could be included in these estimates; none of these 3 patients was included in either the efficacy or safety analyses (see Figure and text ). Data are expressed as No. (%) unless otherwise indicated. †Previous venous thromboembolism or active malignancy was noted for these patients; because this information was not specified for all patients, this number may be an underestimate. *Four patients randomized to unfractionated heparin and 1 patient randomized to low-molecular-weight heparin did not receive any study drug. †The low-molecular-weight heparin was dalteparin in 261 patients and enoxaparin in 91 patients. ‡The percentage of time spent in each international normalized ratio (INR) category while receiving warfarin during 3 months of follow-up was calculated for each patient by linear interpolation.
spond to antifactor Xa heparin levels of 0.35 U/mL and 0.7 U/mL, respectively (ie, the therapeutic range for intravenous heparin in Hamilton, Ontario). The APTT results were not available to the clinical centers or to the central adjudication committee.
RESULTS
Study Patients and Treatment
Patients were enrolled at 6 clinical centers between September 1, 1998, and February 29, 2004 . A total of 2430 patients were initially assessed as meeting the inclusion criteria, of whom 1140 had at least 1 exclusion criterion and 582 others were eligible but refused to participate (Figure) . The remaining 708 patients were registered and randomized to receive unfractionated heparin (355 patients) or low-molecular-weight heparin (353 patients) (TABLE 1). Patients in the 2 groups had similar baseline characteristics (Table 1 ). Eighty percent of the patients had symptomatic deep vein thrombosis without symptoms of pulmonary embolism, 19% had symptomatic pulmonary embolism, and 1% had asymptomatic deep vein thrombosis; 68% were outpatients and 32% were inpatients at diagnosis. For unfractionated heparin, a mean first dose corresponding to 320 U/kg of body weight was given; subsequent doses were a mean of 249 U/kg (TABLE 2). For low-molecular-weight heparin (dalteparin in 74% and enoxaparin in 26% of patients), the mean dose corresponded to 99 IU/kg (Table 2 ). Study drug was given for a mean of 6.3 days in the unfractionated heparin group and 7.1 days in the low-molecular-weight heparin group (Table 2 ) and was stopped before the fifth day of treatment in 84 unfractionated heparin group patients and 44 lowmolecular-weight heparin group patients, most commonly because the international normalized ratio was greater than 3.0. One patient stopped study drug prematurely because of thrombocytopenia (low-molecularweight heparin group); heparininduced thrombocytopenia was not suspected. Only 1 patient who prematurely stopped study drug was subsequently given the alternative therapy (unfractionated heparin group). Treatment was administered entirely in the outpatient setting in 72% of the unfractionated heparin group and 68% of the lowmolecular-weight heparin group (P= .29) ( Table 2 ).
Recurrent Venous Thromboembolism
Recurrent venous thromboembolism occurred in 13 (3.8%) of 345 patients in the unfractionated heparin group and 12 (3.4%) of 352 patients in the low-molecular-weight heparin group (difference, 0.4%; 95% confidence interval, −2.6% to 3.3%; hypothesis supporting assumptions for noninferiority, P = .002) (TABLE 3). The recurrent episode of venous thromboembolism was a pulmonary embolism in 2 patients in the unfractionated heparin group (neither was fatal) and in 4 patients in the low-molecular-weight heparin group (1 was fatal; a sudden unexplained death 81 days after enrollment); the remaining episodes were deep vein thrombosis. An additional 41 patients in the unfractionated heparin group and 40 patients in the low-molecular-weight heparin group had investigation for and exclusion of suspected venous thromboembolism during follow-up.
Bleeding
During the first 10 days, major bleeding occurred in 4 (1.1%) of 348 patients in the unfractionated heparin group and 5 (1.4%) of 352 patients in the low-molecular-weight heparin group (difference, −0.3%; 95% confidence interval, −2.3% to 1.7%). During 3 months of follow-up, major bleeding occurred in 6 patients (1.7%) in the unfractionated heparin group and 12 patients (3.4%) in the low-molecular-weight heparin group (difference, −1.7%; 95% confidence interval, −4.3% to 0.8%). Of the major bleeding events, 1 in the unfractionated heparin group (a subdural hematoma associated with trauma 68 days after enrollment) and 1 in the low-molecularweight heparin group (an epidural hematoma 3 days after enrollment) were fatal. There was 1 other nonfatal intracranial bleed in the low-molecularweight heparin group (intracerebral *Recurrent venous thromboembolism in the first 10 days and in the entire 3 months occurred in 2 (0.7%) and 9 (3.4%) who received dalteparin and in 0 and 3 (3.3%) who received enoxaparin, respectively. †Major bleeding in the first 10 days and in the entire 3 months occurred in 5 (1.9%) and 10 (3.8%) who received dalteparin and in 0 and 2 (2.2%) who received enoxaparin.
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©2006 American Medical Association. All rights reserved. bleeding associated with a fall 26 days after enrollment). Only 1 patient had both a major bleeding event (15 days after enrollment) and recurrent venous thromboembolism (27 days after enrollment, while receiving warfarin). Total bleeding, which included major and minor bleeding, was not significantly different between the 2 groups at 10 days or at 3 months (Table 3) .
Deaths
There were 18 deaths in the unfractionated heparin group and 22 deaths in the low-molecular-weight heparin group. Causes of death in the unfractionated heparin group were bleeding in 1, cancer in 13, and other causes in 4 and in the low-molecular-weight heparin group were pulmonary embolism in 3 (2 occurred after diagnosis of recurrent nonfatal venous thromboembolism), bleeding in 1, cancer in 16, and other causes in 2.
APTT Values and Clinical Outcomes in the Unfractionated Heparin Group
The APTT was measured midway between injections (a mean of 6.0 hours after the morning dose) a mean of 2. 26 drug costs for a 6-day course of treatment for a patient weighing 80 kg would be $712 for low-molecular-weight heparin and $37 for unfractionated heparin. These calculations assume that both drugs are administered in the regimens used in this study (ie, twice daily, with use of multidose vials).
This study has a number of potential weaknesses that need to be considered. First, the open-label design could have led to a biased assessment of outcomes during follow-up. This is unlikely because a central adjudication committee that was blinded to treatment allocation assessed all outcomes using standardized criteria. In addition, because a similar number of patients in each group had a negative evaluation for venous thromboembolism during follow-up, there is no evidence to suggest that the clinical centers had different thresholds for investigating patients for recurrent thrombosis in the 2 groups.
Second, the total number of patients included in the study was lower than originally planned because of slow enrollment. Although the smaller sample size reduces the precision of the findings, we still are able to confirm our hypothesis that the unfractionated heparin regimen is not inferior to lowmolecular-weight heparin (P=.002 for noninferiority). Furthermore, our data show that it is very unlikely that there is as much as a 3.3% higher frequency of recurrent venous thromboembolism with unfractionated heparin (Table 3) , thereby satisfying the criteria recently used to conclude that fondaparinux and ximelagatran were not inferior to standard therapy for treatment of acute venous thromboembolism. [27] [28] [29] A power calculation was performed after the study results were known. For this calculation, we assumed that there were 348 patients in each treatment group. Using the observed recurrent venous thromboembolism proportion of 3.6% as expected in each group, a 1-sided ␣ level of .05, and a power of 90%, the noninferiority margin is 4.1%. That is, a frequency of recurrent venous thromboembolism in the unfractionated heparin group during follow-up of 7.7% (3.6% plus 4.1%) or greater can be excluded under the noninferiority hypothesis. Therefore, because the proportion of patients who developed recurrent venous thromboembolism was lower than expected (ie, 3.6% vs 6.0%) despite reduced enrollment (ie, 697 vs 824 patients), the study has greater power (ie, 97%) to detect an absolute increase of recurrent venous thromboembolism of 5% in the unfractionated heparin group. However, with the expression of the noninferiority margin in relative terms, the reduced sample size and lower recurrent venous thromboembolism proportion produces a larger noninferiority risk ratio of 2.14 (7.7%/3.6%) instead of the 1.83 ratio associated with the original parameters (11%/6%).
A third potential limitation is that there were more postrandomization exclusions in the unfractionated heparin group than in the low-molecularweight heparin group (10 vs 1) and that the decision to exclude these patients may have been influenced by the openlabel study design. However, as the decision to exclude randomized patients FIXED-DOSE UNFRACTIONATED HEPARIN FOR VENOUS THROMBOEMBOLISM from the final analysis was made by the steering committee without knowledge of treatment allocation, and as only 2 of the 11 postrandomization exclusions (Figure) were due to patient or physician preference (both patients were allocated to the unfractionated heparin group), it is unlikely that postrandomization exclusions biased the study results.
Strengths of this study include that the method of random allocation ensured that clinical centers could not anticipate or influence the group to which patients were allocated (ie, there was effective concealment), 30 that there was no loss to follow-up of patients who were eligible for the analysis of efficacy, that suspected episodes of recurrent venous thromboembolism were investigated in a standardized manner, and that all outcomes were evaluated by an independent central adjudication committee.
Two changes in clinical practice occurred in the course of the study that made it more difficult to enroll patients. First, once-daily low-molecularweight heparin became acceptable for treatment of acute venous thromboembolism, 31 and second, low-molecularweight heparin became preferred over warfarin therapy for long-term treatment of venous thromboembolism in patients with cancer. 32 We conclude that fixed-dose subcutaneous unfractionated heparin is as effective and safe as low-molecularweight heparin for initial treatment of patients with venous thromboembolism and is suitable for treatment at home. In addition, the results of this study question the value of APTT monitoring in patients who are treated with currently recommended doses of unfractionated heparin.
